SE8900542D0 - Administreringssystem foer farmakologiska medel - Google Patents

Administreringssystem foer farmakologiska medel

Info

Publication number
SE8900542D0
SE8900542D0 SE8900542A SE8900542A SE8900542D0 SE 8900542 D0 SE8900542 D0 SE 8900542D0 SE 8900542 A SE8900542 A SE 8900542A SE 8900542 A SE8900542 A SE 8900542A SE 8900542 D0 SE8900542 D0 SE 8900542D0
Authority
SE
Sweden
Prior art keywords
agent
stable
microspheres
proteinoid
encapsulated
Prior art date
Application number
SE8900542A
Other languages
English (en)
Other versions
SE502324C2 (sv
SE8900542L (sv
Inventor
S S Steiner
Original Assignee
Clinical Technologies Ass
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clinical Technologies Ass filed Critical Clinical Technologies Ass
Publication of SE8900542D0 publication Critical patent/SE8900542D0/sv
Publication of SE8900542L publication Critical patent/SE8900542L/sv
Publication of SE502324C2 publication Critical patent/SE502324C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/559—Redox delivery systems, e.g. dihydropyridine pyridinium salt redox systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE8900542A 1986-08-18 1989-02-16 Administreringssystem för farmakologiskt aktiva medel som är inkapslade i skyddande proteinoidmikrosfärer SE502324C2 (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89736186A 1986-08-18 1986-08-18
PCT/US1987/002025 WO1988001213A1 (en) 1986-08-18 1987-08-14 Delivery systems for pharmacological agents
CA000554255A CA1323305C (en) 1986-08-18 1987-12-14 Delivery systems for pharmacological agents

Publications (3)

Publication Number Publication Date
SE8900542D0 true SE8900542D0 (sv) 1989-02-16
SE8900542L SE8900542L (sv) 1989-02-16
SE502324C2 SE502324C2 (sv) 1995-10-02

Family

ID=25671632

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8900542A SE502324C2 (sv) 1986-08-18 1989-02-16 Administreringssystem för farmakologiskt aktiva medel som är inkapslade i skyddande proteinoidmikrosfärer

Country Status (11)

Country Link
US (1) US4925673A (sv)
EP (2) EP0545913B1 (sv)
JP (1) JP2876058B2 (sv)
AU (1) AU610083B2 (sv)
CA (1) CA1323305C (sv)
CH (1) CH671155A5 (sv)
GB (1) GB2217201B (sv)
NL (1) NL8720442A (sv)
NO (1) NO178055C (sv)
SE (1) SE502324C2 (sv)
WO (1) WO1988001213A1 (sv)

Families Citing this family (460)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GR1000047B (el) * 1988-02-04 1990-05-11 Clinical Technologies Ass Συστηματα χορηγησης φαρμακολογικων παραγοντων.
US5023080A (en) * 1988-06-17 1991-06-11 Basic Bio Systems, Inc. Time release protein
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5041292A (en) * 1988-08-31 1991-08-20 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
CA2018064C (en) * 1989-06-08 1996-04-16 Kaspar Saner Force transducer and method of producing it
EP0550436A1 (en) * 1989-11-06 1993-07-14 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
CA2086323C (en) 1990-07-17 2002-05-14 Rodger P. Mcever Functionally active selectin-derived peptides and ligand for gmp-140
US5693338A (en) * 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5451410A (en) * 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US5443841A (en) * 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US6331318B1 (en) * 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5578323A (en) * 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5447728A (en) * 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US6099856A (en) * 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5714167A (en) * 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US6309639B1 (en) * 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5766886A (en) * 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
EP0656904A1 (en) * 1992-05-28 1995-06-14 Centocor Inc. Peptide inhibitors of selectin binding
EP0652897A4 (en) * 1992-05-28 1995-09-20 Centocor Inc PEPTID INHIBITORS AGAINST SELECTIVITY.
US6916489B2 (en) * 1992-06-15 2005-07-12 Emisphere Technologies, Inc. Active agent transport systems
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5811127A (en) * 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5753617A (en) * 1992-09-08 1998-05-19 Centocor, Inc. Peptide inhibitors of cellular adhesion
WO1994005314A1 (en) * 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of leukocyte adhesion
WO1994007367A1 (en) * 1992-09-29 1994-04-14 Apollon, Inc. Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids
EP0646000A4 (en) * 1992-11-16 1997-05-02 Univ Mercer COMPOSITIONS CONTAINING MICRO-ENCODED NEUTRALIZING ANTIBODIES.
WO1994014836A1 (en) * 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
US5401516A (en) * 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5643957A (en) * 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5709861A (en) * 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US6461643B2 (en) * 1993-04-22 2002-10-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
DE69434418T2 (de) * 1993-04-22 2005-12-22 Emisphere Technologies, Inc. Orale Dareichungsform
US5958457A (en) * 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US20010003001A1 (en) 1993-04-22 2001-06-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1994028878A1 (en) * 1993-06-14 1994-12-22 Emisphere Technologies, Inc. Proteinoid carriers
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
JP2930421B2 (ja) * 1994-02-28 1999-08-03 メディノヴァ メディカル コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤組成物、その製造方法及びその使用方法
EP0759979A4 (en) * 1994-05-10 1999-10-20 Gen Hospital Corp ANTISENSE OLIGONUCLEOTIDES INHIBITION OF HEPATITIS C VIRUS
US5962322A (en) * 1996-11-15 1999-10-05 Massachusetts Institute Of Technology Methods for modulation of cholesterol transport
US7078511B1 (en) 1994-06-23 2006-07-18 Massachusette Institute Of Technology Class BI and CI scavenger receptors
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6124439A (en) * 1994-08-17 2000-09-26 The Rockefeller University OB polypeptide antibodies and method of making
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US5898066A (en) * 1994-08-26 1999-04-27 Children's Medical Center Corporation Trophic factors for central nervous system regeneration
US5654273A (en) * 1994-09-22 1997-08-05 Children's Medical Center Corporation Synducin mediated modulation of tissue repair
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US6090958A (en) * 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1997036480A1 (en) * 1996-03-29 1997-10-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5965121A (en) * 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) * 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5820881A (en) * 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
US5759539A (en) * 1995-06-06 1998-06-02 Georgia Research Foundation, Inc. Method for rapid enzymatic alcohol removal
US5824345A (en) * 1995-06-07 1998-10-20 Emisphere Technologies, Inc. Fragrances and flavorants
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
US5667806A (en) * 1995-06-07 1997-09-16 Emisphere Technologies, Inc. Spray drying method and apparatus
US6051258A (en) * 1995-06-07 2000-04-18 Emisphere Technologies, Inc. Proteinoid emulsions and methods for preparation and use thereof
US5750147A (en) * 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
DE19681560T1 (de) * 1995-09-11 1998-08-20 Emisphere Tech Inc Verfahren zur Herstellung von omega-Aminoalkansäure-Derivaten aus Cycloalkanonen
ATE192334T1 (de) † 1995-11-09 2000-05-15 Microbiological Res Authority Mikroverkapselte dna zur impfung und gentherapie
US5925333A (en) * 1995-11-15 1999-07-20 Massachusetts Institute Of Technology Methods for modulation of lipid uptake
US5843884A (en) * 1995-11-15 1998-12-01 Oklahoma Medical Research Foundation C9 complement inhibitor
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) * 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US5888982A (en) * 1996-04-01 1999-03-30 President And Fellows Of Harvard College Regulation of vascular smooth muscle cell heme oxygenase-1
CA2258264A1 (en) 1996-06-14 1997-12-18 Emisphere Technologies, Inc. Microencapsulated fragrances and method for preparation
US6004749A (en) * 1996-07-31 1999-12-21 Message Pharmaceuticals Method for identifying compounds affecting RNA/RNA binding protein interactions
US5859227A (en) * 1996-07-31 1999-01-12 Bearsden Bio, Inc. RNA sequences which interact with RNA-binding proteins
US6107029A (en) * 1996-07-31 2000-08-22 Message Pharmaceticals, Inc. Universal method for detecting interactions between RNA molecules and RNA binding proteins
AU5243798A (en) 1996-11-06 1998-05-29 Children's Medical Center Corporation Transgenic animal expressing a syndecan in the regions of hypothalamus
ATE291588T1 (de) 1996-11-08 2005-04-15 Oklahoma Med Res Found Endothel-spezifischer expression unter einfluss von epcr kontrollelementen
EP0886471A4 (en) 1996-11-18 2002-07-17 Emisphere Tech Inc METHODS AND COMPOSITIONS FOR INDUCING ORAL TOLERANCE IN MUZZLES
US6358504B1 (en) * 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5804688A (en) * 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US5990166A (en) * 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1015008B1 (en) 1997-02-07 2015-08-05 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5879681A (en) * 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5939381A (en) * 1997-02-07 1999-08-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6060513A (en) * 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5876710A (en) * 1997-02-07 1999-03-02 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US5863944A (en) * 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5962710A (en) * 1997-05-09 1999-10-05 Emisphere Technologies, Inc. Method of preparing salicyloylamino acids
WO1999011288A1 (en) * 1997-09-05 1999-03-11 Massachusetts Institute Of Technology Sr-bi antagonists and use thereof as contraceptives and in the treatment of steroidal overproduction
US7166568B1 (en) 1998-02-09 2007-01-23 Oklahoma Medical Research Foundation Compositions and methods to inhibit formation of the C5b-9 complex of complement
US6858706B2 (en) 1998-04-07 2005-02-22 St. Jude Children's Research Hospital Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
US6331407B1 (en) 1998-05-06 2001-12-18 St. Jude Children's Research Hospital Antibiotics and methods of using the same
US6448224B1 (en) 1998-05-06 2002-09-10 St. Jude Children's Research Hospital Antibiotics and methods of using the same
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
WO2000006534A1 (en) 1998-07-27 2000-02-10 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6440929B1 (en) 1998-07-27 2002-08-27 Emisphere Technologies, Inc. Pulmonary delivery of active agents
EP1102742B1 (en) * 1998-08-07 2006-06-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6991798B1 (en) 1998-08-07 2006-01-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
US6921825B2 (en) 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
EP1119625B1 (en) 1998-10-07 2005-06-29 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
DE19848002A1 (de) 1998-10-17 2000-04-20 Goldschmidt Ag Th Polypeptid-Polysiloxan-Copolymere
SI2319928T1 (sl) 1998-10-23 2013-08-30 Kirin-Amgen, Inc. Dimerni trombopoietinski peptidni mimetiki, ki se veĺ˝ejo na receptor mp1 in imajo trombopoietinsko aktivnost
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
FR2786098B1 (fr) 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
US6773911B1 (en) * 1998-11-23 2004-08-10 Amgen Canada Inc. Apoptosis-inducing factor
CA2358463A1 (en) * 1999-01-08 2000-07-13 Virginia Commonwealth University Polymeric delivery agents and delivery agent compounds
JP4637365B2 (ja) 1999-02-26 2011-02-23 エミスフェアー・テクノロジーズ・インク 活性剤デリバリーのための化合物及び組成物
US7018654B2 (en) * 1999-03-05 2006-03-28 New River Pharmaceuticals Inc. Pharmaceutical composition containing an active agent in an amino acid copolymer structure
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2000069898A2 (en) 1999-05-14 2000-11-23 Arbor Vita Corporation Molecular interactions in allergy cells
WO2000074736A1 (en) 1999-06-04 2000-12-14 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US7361684B2 (en) * 1999-06-28 2008-04-22 Massachusetts Institute Of Technology Screening of compounds for treatment of atherosclerosis and heart attack
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US7671029B2 (en) * 1999-08-06 2010-03-02 Immupharma Sa Compositions and methods for enhanced pharmacological activity of compositions comprising peptide drug substances
US6908900B2 (en) * 2001-01-17 2005-06-21 Zimmer & Associates Ag Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients
US20030060413A1 (en) * 2001-09-06 2003-03-27 Zimmer Robert H. Derivatives of pseudo-peptides, their preparation and their biological uses
EP1140136B1 (en) * 1999-09-03 2007-05-16 Amgen Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2001037803A2 (en) 1999-11-15 2001-05-31 Biocure, Inc. Responsive polymeric hollow particles
FR2801226B1 (fr) 1999-11-23 2002-01-25 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation
WO2001039722A2 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
AU2001257173B2 (en) 2000-04-21 2005-09-22 Amgen Inc. Apo-ai/aii peptide derivatives
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
DE10026699A1 (de) * 2000-05-30 2001-12-06 Basf Ag Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
FR2814952B1 (fr) 2000-10-06 2004-01-02 Flamel Tech Sa Suspension colloidale de particules submicromiques de vectorisation de principes actifs et leur mode de preparation
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US6565888B1 (en) 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20030225300A1 (en) * 2001-04-19 2003-12-04 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
EP2292655B1 (en) 2001-05-11 2012-03-14 Amgen SF, LLC Peptides and related molecules that bind to tall-1
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
EP1429650B1 (en) * 2001-08-30 2009-06-24 Mount Sinai School of Medicine of New York University Alternatively spliced circulating tissue factor
WO2003020702A2 (en) 2001-08-31 2003-03-13 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
KR20100120246A (ko) 2001-11-14 2010-11-12 센토코 오르토 바이오테크 인코포레이티드 항 ｉｌ-6 항체, 조성물, 방법 및 용도
US20030138975A1 (en) * 2001-12-20 2003-07-24 Kimberly-Clark Worldwide, Inc. Diagnostic signal amplification with proteinoid microspheres
US7056535B2 (en) * 2001-12-20 2006-06-06 Kimberly-Clark Worldwide, Inc. Triggered release from proteinoid microspheres
WO2003057165A2 (en) 2002-01-04 2003-07-17 The Rockefeller University COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US6939554B2 (en) * 2002-02-05 2005-09-06 Michigan Biotechnology Institute Antimicrobial polymer
EP2963017A1 (en) 2002-03-11 2016-01-06 Molecular Insight Pharmaceuticals, Inc. Technetium-dipyridine complexes, and methods of use thereof
SI1494732T1 (sl) 2002-03-20 2008-08-31 Mannking Corp Inhalacijski aparat
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
WO2003084518A2 (fr) 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules de principes actifs
US7208467B2 (en) 2002-06-07 2007-04-24 Monty Krieger Lipid-altering compositions for the treatment of infertility
FR2840614B1 (fr) 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
CA2490409A1 (en) 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
EP1546184A4 (en) * 2002-07-16 2006-08-23 Univ South Florida HUMAN IMMUNOSUPPRESSIVE PROTEIN
MXPA05002219A (es) 2002-08-28 2005-07-05 Immunex Corp Composiciones y metodos para tratar una enfermedad cardiovascular.
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
CA2501685A1 (en) * 2002-10-08 2004-04-22 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
ATE426575T1 (de) 2003-01-07 2009-04-15 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
EP3299465A1 (en) 2003-03-07 2018-03-28 DSM IP Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
LT2335725T (lt) 2003-04-04 2017-01-25 Genentech, Inc. Didelės koncentracijos antikūno ir baltymo kompozicijos
US20060246104A1 (en) * 2003-04-16 2006-11-02 Massia Stephen P Stable rgd peptidomimetic composition
JP2007515939A (ja) 2003-05-09 2007-06-21 セントカー・インコーポレーテツド ＩＬ−２３ｐ４０特異的免疫グロブリン由来タンパク質、組成物、方法および用途
NZ544024A (en) 2003-05-12 2009-06-26 Affymax Inc Novel poly(ethylene glycol) modified compounds and uses thereof
EA010015B1 (ru) 2003-05-12 2008-06-30 Афимакс, Инк. Новый разделительный фрагмент (спейсер) для модифицированных полиэтиленгликолем соединений на основе пептидов
ATE478963T1 (de) 2003-07-03 2010-09-15 Univ New Jersey Med Gene als diagnostische werkzeuge für autismus
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
EP1658273B1 (en) * 2003-08-20 2007-01-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
ATE361294T1 (de) * 2003-08-20 2007-05-15 Lilly Co Eli Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagonartigen peptid (glp)-1-verbindung oder eines melanocortin-4- rezeptor-(mc4-)agonistschen peptids
US20050233435A1 (en) * 2003-09-04 2005-10-20 Nyu Medical Center Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
EP2335694B1 (en) * 2003-09-15 2018-06-13 NanoPharmaceuticals LLC Thyroid hormone analogs and methods of use
CA2540407A1 (en) * 2003-09-25 2005-03-31 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
US7625707B2 (en) * 2003-10-02 2009-12-01 Ramot At Tel Aviv University Ltd. Antibacterial agents and methods of identifying and utilizing same
US20050158741A1 (en) 2003-11-14 2005-07-21 Children's Hospital Self-cleaving ribozymes and uses thereof
US7858322B2 (en) 2003-12-23 2010-12-28 Nono, Inc. Method of determining inhibition of binding to TRPM7 protein
PT1740154E (pt) * 2004-03-12 2009-09-11 Biodel Inc Composições de insulina com absorção melhorada
KR101289774B1 (ko) 2004-03-31 2013-08-07 다나-파버 캔서 인스티튜트 인크. 표피성장인자 수용체를 표적으로 하는 치료에 대한 암의반응성을 결정하는 방법
US7252446B2 (en) * 2004-03-31 2007-08-07 Brother Kogoy Kabushiki Kaisha Image forming apparatus
AU2005231359A1 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human GLP-1 mimetibodies, compositions, methods and uses
WO2005098008A1 (en) * 2004-04-05 2005-10-20 Massachusetts Institute Of Technology Lipid-diet inducible heart attack murine model
CA2566609C (en) 2004-05-13 2012-06-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
CA2567883A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
JP5209302B2 (ja) 2004-06-15 2013-06-12 ポリメディックス、インク． ポリカチオン化合物とその使用
EP1773400A2 (en) * 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
US20090156471A1 (en) * 2004-07-15 2009-06-18 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
EP1781310B1 (en) * 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
ATE539745T1 (de) 2004-08-19 2012-01-15 Univ Tel Aviv Future Tech Dev Zusammensetzungen zur behandlung von amyloid- assoziierten erkrankungen
JP5078014B2 (ja) 2004-08-20 2012-11-21 マンカインド コーポレイション ジケトピペラジン合成の触媒反応
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
US7786086B2 (en) * 2004-09-08 2010-08-31 Ramot At Tel-Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
ES2629397T3 (es) * 2004-09-24 2017-08-09 Amgen Inc. Moléculas de Fc modificadas
CN1296098C (zh) * 2004-09-29 2007-01-24 薛南荣 口服胰岛素保护剂
US7892540B2 (en) 2004-10-06 2011-02-22 Mayo Foundation For Medical Education And Research B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
CN101142234A (zh) * 2004-11-11 2008-03-12 阿费麦克斯公司 结合红细胞生成素受体的新肽
US7919093B2 (en) 2004-11-16 2011-04-05 Trustees Of Boston University Roles for dual endothelin-1/angiotensin II receptor (Dear) in hypertension and angiogenesis
EP1853289A4 (en) 2005-01-31 2008-04-09 Vaxinnate Corp NOVEL POLYPEPTIDE LIGANDS FOR THE GREAT ARTICLE RECEPTOR 2
EP1885356A2 (en) * 2005-02-17 2008-02-13 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
PE20061324A1 (es) 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) * 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
NZ564243A (en) 2005-06-08 2011-03-31 Dana Farber Cancer Inst Inc Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1) pathway
EP1896073B1 (en) 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP1928423B1 (en) 2005-09-14 2015-12-09 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US9220788B2 (en) * 2009-06-17 2015-12-29 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US20090022806A1 (en) * 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
WO2007035612A2 (en) * 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
EP1973928A2 (en) * 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Self-assembled fmoc-ff hydrogels
AR056142A1 (es) * 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
US7879212B2 (en) * 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
ES2517420T3 (es) 2005-12-29 2014-11-03 Janssen Biotech, Inc. Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
US20100015642A1 (en) * 2006-01-05 2010-01-21 Kwon Eugene D B7-h1 and survivin in cancer
US20090215084A1 (en) * 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
US20070208074A1 (en) * 2006-01-24 2007-09-06 Bonni Azad M Methods and compositions for treating and preventing tumors
WO2007092314A2 (en) 2006-02-02 2007-08-16 Verenium Corporation Esterases and related nucleic acids and methods
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US7786090B2 (en) * 2006-03-01 2010-08-31 President And Fellows Of Harvard College Methods and compositions for treating and preventing neurologic disorders
US20100034819A1 (en) * 2006-03-31 2010-02-11 Centocor Inc. Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions on renal disease associated anemia
WO2007124361A2 (en) * 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
EP3147365B1 (en) 2006-04-21 2019-12-04 Intervet International B.V. Pestivirus species
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
WO2007137163A2 (en) * 2006-05-19 2007-11-29 Georgia Tech Research Corporation Abc transporter ligand
US20080242608A1 (en) * 2006-06-02 2008-10-02 Azad Bonni Methods and compositions for treating and preventing neurologic disorders
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
US7960606B2 (en) * 2006-06-20 2011-06-14 The J. David Gladstone Institutes Mouse model of chronic heart failure and coronary atherosclerosis regression
EP2452683A3 (en) 2006-06-26 2012-08-22 Amgen Inc. Methods for treating atherosclerosis
US20100112600A1 (en) * 2006-07-13 2010-05-06 Azard Bonni Methods and compositions for modulating synapse formation
WO2008008873A2 (en) * 2006-07-14 2008-01-17 Georgia Tech Research Corporation Clc channel ligand
US7825093B2 (en) 2006-10-25 2010-11-02 Amgen Inc. Methods of using OSK1 peptide analogs
EP2605015A1 (en) * 2006-11-10 2013-06-19 Dimerix Bioscience Pty.Ltd. Kits for determining the interaction of a test compound with two associated receptors
CN101605797A (zh) 2006-11-13 2009-12-16 伊莱利利公司 治疗炎症疾病和癌症的噻吩并嘧啶酮
AR064623A1 (es) * 2006-12-21 2009-04-15 Centocor Inc Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
AU2007353426A1 (en) * 2006-12-22 2008-11-20 Albany College Of Pharmacy And Health Sciences Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
WO2008083169A2 (en) * 2006-12-26 2008-07-10 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
US20090142342A1 (en) * 2006-12-27 2009-06-04 Johns Hopkins University B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
CN101663323A (zh) 2006-12-27 2010-03-03 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
AU2007339762B2 (en) 2006-12-27 2011-03-31 The Johns Hopkins University Compositions and methods for treating inflammation and auto-immune diseases
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
WO2008094275A1 (en) 2007-01-30 2008-08-07 New York University Peptides for treatment of conditions associated with nitric oxide
CA2840407A1 (en) * 2007-05-22 2008-12-18 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
WO2008148023A2 (en) * 2007-05-23 2008-12-04 Medical College Of Georgia Research Institute, Inc. Compositions and methods for treating neurological disorders
AU2008293885A1 (en) * 2007-07-13 2009-03-05 The John Hopkins University B7-DC variants
UA103304C2 (ru) 2007-07-26 2013-10-10 Эмджен Инк. Модифицированный белок лецитин-холестерин ацилтрансферазы (lcat)
CN101848918A (zh) * 2007-09-07 2010-09-29 吉奇亚公司 线粒体组合物及其用途
JP2010540618A (ja) * 2007-10-02 2010-12-24 アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド 幼児の成長および発達を増大するための内在性カンナビノイド
US8932558B2 (en) * 2007-10-05 2015-01-13 Plaxgen Inc Multi-subunit biological complexes for treatment of plaque-associated diseases
WO2009058997A2 (en) * 2007-11-01 2009-05-07 Biocept Inc. Non-invasive isolation of fetal nucleic acid
CN101951957A (zh) * 2008-01-04 2011-01-19 百达尔公司 胰岛素释放作为组织的葡萄糖水平的函数的胰岛素制剂
BRPI0906797A2 (pt) * 2008-01-09 2015-07-14 Molecular Insight Pharm Inc Inibidores de anidrase carbônica ix
US20110020325A1 (en) * 2008-02-29 2011-01-27 Kwon Eugene D Methods for reducing granulomatous inflammation
CN105363034A (zh) * 2008-05-23 2016-03-02 香港大学 治疗流感的联合疗法
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
KR101558026B1 (ko) 2008-06-13 2015-10-06 맨카인드 코포레이션 건조 분말 흡입기 및 약물 투여 시스템
CA2728523C (en) 2008-06-20 2020-03-10 Mannkind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
US20100008900A1 (en) * 2008-07-14 2010-01-14 The University Of Hong Kong Annexin ii compositions for treating or monitoring inflammation or immune-mediated disorders
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8563697B2 (en) 2008-08-14 2013-10-22 Cephalon Australia Pty. Ltd. Anti-IL-12/IL-23 antibodies
JP2012500197A (ja) 2008-08-15 2012-01-05 ジョージタウン ユニバーシティー Ｒａｓｓｆ１ａ発現およびヒト癌細胞増殖の蛍光調節剤
NZ591234A (en) * 2008-08-22 2012-03-30 Sanofi Aventis [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
US20110223188A1 (en) * 2008-08-25 2011-09-15 Solomon Langermann Targeted costimulatory polypeptides and methods of use to treat cancer
US8357503B2 (en) 2008-08-29 2013-01-22 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8153391B2 (en) 2008-08-29 2012-04-10 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
ES2589915T3 (es) 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
WO2010046778A2 (en) * 2008-10-21 2010-04-29 International Vaccine Institute Novel shigella frotein antigens and methods
US8278419B2 (en) 2008-10-31 2012-10-02 Centocor Ortho Biotech Inc. Fibronectin type III domain based scaffold compositions, methods and uses
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
NZ611764A (en) 2008-11-13 2015-01-30 Gilead Calistoga Llc Therapies for hematologic malignancies
RU2539565C2 (ru) * 2008-12-05 2015-01-20 Моликьюлар Инсайт Фармасьютикалз, Инк. Са-ix специфические радиофармпрепараты для лечения и визуалазиции злокачественных опухолей
WO2010065906A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer
EP2706057B1 (en) 2008-12-05 2016-04-20 Molecular Insight Pharmaceuticals, Inc. Bis(imidazolyl)compounds and radionuclide complexes
WO2010068680A1 (en) 2008-12-10 2010-06-17 Mount Sinai School Of Medicine Of New York University Thelper cell type 17 lineage-specific adjuvants, compositions and methods
AR074776A1 (es) 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
US20100159021A1 (en) * 2008-12-23 2010-06-24 Paul Davis Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2396011T3 (en) 2009-02-12 2016-04-25 Janssen Biotech Inc Fibronectin TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, METHODS AND USES
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
EA019499B1 (ru) 2009-03-24 2014-04-30 ГИЛИЭД КАЛИСТОГА ЭлЭлСи Производные атропоизомеров 2-пуринил-3-толилхиназолинона и способы применения
WO2010120506A1 (en) * 2009-03-31 2010-10-21 Ordway Research Institute, Inc. Combination treatment of cancer with cetuximab and tetrac
SG175259A1 (en) * 2009-04-20 2011-11-28 Gilead Calistoga Llc Methods of treatment for solid tumors
US20110038852A1 (en) * 2009-06-10 2011-02-17 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
EP2440184B1 (en) 2009-06-12 2023-04-05 MannKind Corporation Diketopiperazine microparticles with defined specific surface areas
BR112012000209B8 (pt) 2009-06-15 2021-07-27 Molecular Insight Pharm Inc heterodímeros de ácido glutâmico e seus processos de preparação
WO2011011550A1 (en) 2009-07-21 2011-01-27 Calistoga Pharmaceuticals Inc. Treatment of liver disorders with pi3k inhibitors
FR2955324A1 (fr) 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
AU2010286361A1 (en) 2009-08-31 2012-03-15 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
CN105801550B (zh) 2009-11-05 2019-06-14 理森制药股份公司 新型苯并吡喃激酶调节剂
US20120316187A1 (en) 2009-11-13 2012-12-13 Pangaea Biotech, S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US9321999B2 (en) 2009-11-19 2016-04-26 Solis Biodyne Oü Compositions for increasing polypeptide stability and activity, and related methods
RU2012131280A (ru) 2009-12-23 2014-02-10 Санофи [4-(5-аминометил-2-фторфенил)пиперидин-1-ил]-(1н-пирролопиридинил)метаноны и их синтез
DK2516418T3 (da) 2009-12-23 2014-08-11 Sanofi Sa Pro-drugs af [4[4-(5-aminomethyl-2-fluor-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanoner og syntese deraf
JP6046493B2 (ja) 2010-01-27 2016-12-14 チルドレンズ メディカル センター コーポレーション プロミニン−１の血管新生促進フラグメントおよびその使用
ES2722201T3 (es) 2010-03-22 2019-08-08 Hoffmann La Roche Composiciones y procedimientos útiles para estabilizar formulaciones que contienen proteínas
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
EP2571878B1 (en) 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
ES2961381T3 (es) 2010-06-19 2024-03-11 Memorial Sloan Kettering Cancer Center Anticuerpos anti-GD2
CA2801936C (en) 2010-06-21 2021-06-01 Mannkind Corporation Dry powder drug delivery system and methods
MY184736A (en) 2010-06-24 2021-04-20 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
US20120208855A1 (en) 2010-07-12 2012-08-16 Sanofi Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
EP2601609B1 (en) 2010-08-02 2017-05-17 Population Bio, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
WO2012048002A1 (en) 2010-10-07 2012-04-12 Biodel Inc. Self -assembling tripeptides for stabilising biomolecules
CN102462837B (zh) * 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
WO2012094703A1 (en) 2011-01-11 2012-07-19 Dimerix Bioscience Pty Ltd Combination therapy
US20140031383A1 (en) 2011-02-08 2014-01-30 Dana-Farber Cancer Institute, Inc. Methods for treatment of melanoma
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
AU2012225390B2 (en) 2011-03-08 2015-11-12 Sagimet Biosciences Inc. Heterocyclic modulators of lipid synthesis
JP2014509859A (ja) 2011-03-16 2014-04-24 アムジエン・インコーポレーテツド １７ｎａｖ１．３およびｎａｖ１．７の強力かつ選択的阻害剤
WO2012134975A1 (en) 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
KR101940832B1 (ko) 2011-04-01 2019-01-21 맨카인드 코포레이션 의약 카트리지용 블리스터 패키지
EA024842B9 (ru) 2011-05-04 2017-08-31 Ризен Фармасьютикалз Са Соединения в качестве модуляторов протеинкиназы pi3k
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
PL2751279T3 (pl) 2011-08-31 2018-03-30 St. Jude Children's Research Hospital Sposoby i kompozycje do wykrywania poziomu aktywności lizosomalnej egzocytozy i sposoby zastosowania
JP2014527969A (ja) 2011-09-19 2014-10-23 ジェンシア コーポレイション 改変クレアチン化合物
US10221454B2 (en) 2011-10-10 2019-03-05 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
EP2776053A1 (en) 2011-10-24 2014-09-17 MannKind Corporation Methods and compositions for treating pain
FI3091029T3 (sv) 2011-10-31 2023-03-20 Hoffmann La Roche Formuleringar med antikroppar mot IL13
US11180807B2 (en) 2011-11-04 2021-11-23 Population Bio, Inc. Methods for detecting a genetic variation in attractin-like 1 (ATRNL1) gene in subject with Parkinson's disease
EP2800471A4 (en) 2012-01-06 2015-11-04 Molecular Insight Pharm Inc METAL COMPLEX OF POLY (CARBOXYL) AMINE CONTAINING LIGANDS HAVING AFFINITY FOR CARBON IX ANHYDRASE
CA2863887C (en) 2012-02-09 2023-01-03 Population Diagnostics, Inc. Methods of screening low frequency gdna variation biomarkers for pervasive developmental disorder (pdd) or pervasive developmental disorder - not otherwise specified (pdd_nos)
CN104780932A (zh) 2012-02-29 2015-07-15 伊西康内外科公司 微生物区系的组合物及与其相关的方法
WO2013134288A1 (en) 2012-03-05 2013-09-12 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
NZ629499A (en) 2012-03-30 2016-05-27 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
CN104520315A (zh) 2012-04-24 2015-04-15 迈阿密大学 Perforin 2 对侵袭性且多药耐受的病原体的防御
EP2662079A1 (en) 2012-05-10 2013-11-13 Ordway Research Institute, Inc. Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells
CA2878457C (en) 2012-07-12 2021-01-19 Mannkind Corporation Dry powder drug delivery systems and methods
EP2895621B1 (en) 2012-09-14 2020-10-21 Population Bio, Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
EP2900835A4 (en) 2012-09-27 2016-05-11 Population Diagnotics Inc METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DEVELOPMENTAL DISORDERS
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
WO2014099984A1 (en) 2012-12-20 2014-06-26 Amgen Inc. Apj receptor agonists and uses thereof
HUE035739T2 (en) 2013-01-14 2018-05-28 Molecular Insight Pharm Inc Triazine-based radiopharmaceuticals and radiological imaging agents
US20140255403A1 (en) 2013-03-06 2014-09-11 Hadasit Medical Research Services & Development Ltd. Oral composition comprising a tnf antagonist and use thereof
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
RU2680267C2 (ru) 2013-03-15 2019-02-19 Мемориал Слоан Кеттеринг Кэнсер Сентер Высокоаффинные антитела к gd2
CN105143192B (zh) 2013-03-15 2018-01-23 麦康公司 通过环状α‑N‑保护的氨基酯形成N‑保护的‑3,6‑双(4‑氨基丁基)‑2,5‑哌嗪二酮
EP2968373A2 (en) 2013-03-15 2016-01-20 Gencia Corporation Compositions and methods for treating conditions that affect epidermis
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
WO2014169272A1 (en) 2013-04-12 2014-10-16 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CN105407728A (zh) 2013-07-21 2016-03-16 霍勒拜欧姆公司 用于微生物组表征、监测和治疗的方法和***
WO2015021064A1 (en) 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
PL3041958T3 (pl) 2013-09-04 2020-11-02 Cold Spring Harbor Laboratory Redukcja rozpadu mRNA mediowanego sekwencjami nonsensownymi
EP3052131B1 (en) 2013-10-01 2018-12-05 Mayo Foundation for Medical Education and Research Methods for treating cancer in patients with elevated levels of bim
WO2015074050A1 (en) 2013-11-18 2015-05-21 Nanopharmaceuticals Llc Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof
JP2017502021A (ja) 2013-12-20 2017-01-19 ギリアード カリストガ エルエルシー ホスファチジルイノシトール３−キナーゼ阻害剤のためのプロセス方法
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
EP3083583B1 (en) 2013-12-20 2020-11-18 Sagimet Biosciences Inc. Heterocyclic modulators of lipid synthesis and combinations thereof
BR112016015879B1 (pt) 2014-01-07 2022-06-14 Sagimet Biosciences Inc Composto modulador heterocíclico de síntese de lipídeos, composição farmacêutica que compreende dito composto e uso do mesmo para o tratamento de câncer
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
WO2015149016A2 (en) 2014-03-28 2015-10-01 University Of Washington Through Its Center For Commercialization Breast and ovarian cancer vaccines
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
US10941182B2 (en) 2014-06-10 2021-03-09 Amgen Inc. Apelin polypeptides
CA2952012A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
WO2016011386A1 (en) 2014-07-18 2016-01-21 University Of Washington Cancer vaccine compositions and methods of use thereof
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
US10724096B2 (en) 2014-09-05 2020-07-28 Population Bio, Inc. Methods and compositions for inhibiting and treating neurological conditions
WO2016054240A1 (en) 2014-09-30 2016-04-07 Sean Dalziel Fixed dose combinations for the treatment of viral diseases
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3212001A4 (en) 2014-10-31 2018-04-25 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
SG11201707538XA (en) 2015-03-17 2017-10-30 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
CA2979696A1 (en) 2015-03-19 2016-09-22 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
US10548844B2 (en) 2015-12-14 2020-02-04 Massachusetts Institute Of Technology pH-responsive mucoadhesive polymeric encapsulated microorganisms
CN109069473B (zh) 2016-04-21 2022-09-16 港大科桥有限公司 用于亮肤和减少色素沉着过度的组合物和方法
US10845367B2 (en) 2016-05-04 2020-11-24 Abilita Bio, Inc. Modified multispanning membrane polypeptides and methods of use thereof to screen therapeutic agents
WO2017214299A1 (en) 2016-06-07 2017-12-14 Nanopharmaceuticals, Llc NON-CLEAVABLE POLYMER CONJUGATED WITH αvβ3 INTEGRIN THYROID ANTAGONISTS
JP2019524721A (ja) 2016-07-15 2019-09-05 ポセイダ セラピューティクス， インコーポレイテッド キメラ抗原受容体および使用方法
CN109715670A (zh) 2016-07-15 2019-05-03 波赛达治疗公司 对muc1特异性的嵌合抗原受体(car)及其使用方法
EP3574012A1 (en) 2017-01-27 2019-12-04 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
KR20240038146A (ko) 2017-01-30 2024-03-22 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
WO2018147915A1 (en) 2017-02-07 2018-08-16 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
EA202090681A1 (ru) 2017-10-17 2020-07-21 Ризен Фармасьютикалз Са Модуляторы каналов crac для лечения рака пищевода
WO2019082124A1 (en) 2017-10-26 2019-05-02 Rhizen Pharmaceuticals Sa COMPOSITION AND METHOD FOR THE TREATMENT OF LARGE B-CELL DIFFUSED LYMPHOMA
KR20200079256A (ko) 2017-10-30 2020-07-02 리젠 파마슈티컬스 소시에떼 아노님 혈액암 및 고형암을 치료하기 위한 칼슘 방출-활성화된 칼슘 채널 조절제
CA3084905A1 (en) 2017-12-06 2019-06-13 Rhizen Pharmaceuticals Sa Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma
WO2019126574A1 (en) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Vcar compositions and methods for use
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
JP2021523138A (ja) 2018-05-11 2021-09-02 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ−２３抗体を使用してうつを治療する方法
WO2020001657A1 (en) 2018-06-29 2020-01-02 Wuhan Neurophth Biological Technology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
SG11202012044QA (en) 2018-06-29 2021-01-28 Wuhan Neurophth Biological Tech Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
US20210315826A1 (en) * 2018-07-23 2021-10-14 Cornell University Natural fluorescent polydedral amino acid crystals for efficient entrapment and systemic delivery of hydrophobic small molecules
SI3625368T1 (sl) 2018-08-08 2023-04-28 Pml Screening, Llc Postopki z genetskim testiranjem za oceno tveganja za razvoj progresivne multifokalne levkoencefalopatije, ki jo povzroča virus John Cunningham
AU2019323434A1 (en) 2018-08-20 2021-02-25 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
AU2019349956A1 (en) 2018-09-27 2021-04-29 PhosphoGam Inc. Methods and compositions for the expansion and use of allogeneic gamma/delta-T cells
EP3898993A1 (en) 2018-12-20 2021-10-27 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
AU2020208828A1 (en) 2019-01-15 2021-08-05 Janssen Biotech, Inc. Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis
EA202192038A1 (ru) 2019-01-23 2021-10-05 Янссен Байотек, Инк. Композиции антител к фно для применения в способах лечения псориатического артрита
WO2020183270A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
CN113840837A (zh) 2019-03-14 2021-12-24 詹森生物科技公司 用于产生抗tnf抗体组合物的方法
US20220153830A1 (en) 2019-03-14 2022-05-19 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
MX2021012032A (es) 2019-04-01 2021-11-03 Genentech Inc Composiciones y metodos para estabilizar formulaciones que contienen proteinas.
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
CN113939531A (zh) 2019-06-03 2022-01-14 詹森生物科技公司 用于治疗银屑病关节炎的抗tnf抗体组合物和方法
KR20220030952A (ko) 2019-06-03 2022-03-11 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
EP4025593A1 (en) 2019-09-05 2022-07-13 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
CN114828842A (zh) 2019-10-21 2022-07-29 理森制药股份公司 用于治疗急性髓系白血病的包含dhodh抑制剂的组合物
CN113025633A (zh) 2019-12-09 2021-06-25 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
WO2021127505A1 (en) 2019-12-20 2021-06-24 Poseida Therapeutics, Inc. Anti-muc1 compositions and methods of use
WO2021178707A1 (en) 2020-03-04 2021-09-10 Poseida Therapeutics, Inc. Compositions and methods for the treatment of metabolic liver disorders
US20230121433A1 (en) 2020-03-11 2023-04-20 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
CN115996747A (zh) 2020-04-14 2023-04-21 波赛达治疗公司 用于治疗癌症的组合物和方法
WO2021214587A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating viral infections
WO2021214588A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating coronavirus infections
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US20240060090A1 (en) 2021-02-23 2024-02-22 Poseida Therapeutics, Inc. Genetically modified induced pluripotent stem cells and methods of use thereof
WO2022187671A1 (en) 2021-03-04 2022-09-09 Poseida Therapeutics, Inc. Compositions and methods for the treatment of hemophilia
CN115927472A (zh) 2021-07-05 2023-04-07 武汉纽福斯生物科技有限公司 一种抗vegf抗体体内表达***的构建和应用
US20230042465A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
KR20240034218A (ko) 2021-07-09 2024-03-13 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물을 생산하기 위한 제조 방법
TW202306985A (zh) 2021-07-12 2023-02-16 美商建南德克公司 降低抗體－脂酶結合之結構
KR20240042489A (ko) 2021-08-06 2024-04-02 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 Nd4 돌연변이에 의해 야기되는 레베르 유전성 시신경병증을 치료하기 위한 조성물 및 방법
WO2023017537A1 (en) 2021-08-12 2023-02-16 Celagenex Research (India) Pvt. Ltd. Oral algal oil based gastro-intestinal tract permeable peptide composition
WO2023060088A1 (en) 2021-10-04 2023-04-13 Poseida Therapeutics, Inc. Transposon compositions and methods of use thereof
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists
WO2023164573A1 (en) 2022-02-23 2023-08-31 Poseida Therapeutics, Inc. Genetically modified cells and methods of use thereof
WO2024036273A1 (en) 2022-08-11 2024-02-15 Poseida Therapeutics, Inc. Chimeric cd8-alpha co-receptor compositions and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576758A (en) * 1966-10-17 1971-04-27 Ncr Co Treatment of polypeptide-containing hydrophilic polymeric capsule wall material with uranium and vanadium compounds
US3962416A (en) * 1971-01-25 1976-06-08 Sol Katzen Preserved nutrients and products
CA1045977A (en) * 1973-05-17 1979-01-09 Arthur D. Little Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4357259A (en) * 1977-08-01 1982-11-02 Northwestern University Method of incorporating water-soluble heat-sensitive therapeutic agents in albumin microspheres
US4217370A (en) * 1977-08-25 1980-08-12 Blue Wing Corporation Lipid-containing feed supplements and foodstuffs
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4298002A (en) * 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
US4483807A (en) * 1981-01-27 1984-11-20 Japan Atomic Energy Research Institute Process for producing a slow release composite
JPS583511A (ja) * 1981-06-25 1983-01-10 住友電気工業株式会社 ケ−ブル接続部の防水方法
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
CA1196862A (en) * 1983-06-01 1985-11-19 Anthony M.F. Sun Microencapsulation of living tissue and cells
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
FR2565102B1 (fr) * 1984-06-05 1987-03-20 Paris Sud Universite Microcapsules biodegradables a base de serumalbumine, leur preparation et leur application a la liberation in situ de medicuments
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system

Also Published As

Publication number Publication date
EP0545913B1 (en) 1999-02-24
CA1323305C (en) 1993-10-19
SE502324C2 (sv) 1995-10-02
EP0318512A4 (en) 1989-06-14
WO1988001213A1 (en) 1988-02-25
CH671155A5 (sv) 1989-08-15
AU7875287A (en) 1988-03-08
NO178055C (no) 1996-01-17
GB8830377D0 (en) 1989-03-08
NO881664L (no) 1988-04-18
US4925673A (en) 1990-05-15
NO178055B (no) 1995-10-09
JP2876058B2 (ja) 1999-03-31
NO881664D0 (no) 1988-04-18
EP0545913A1 (en) 1993-06-09
SE8900542L (sv) 1989-02-16
GB2217201B (en) 1991-01-23
EP0318512B1 (en) 1998-06-17
GB2217201A (en) 1989-10-25
AU610083B2 (en) 1991-05-16
EP0318512A1 (en) 1989-06-07
JPH02500669A (ja) 1990-03-08
NL8720442A (nl) 1989-04-03

Similar Documents

Publication Publication Date Title
SE8900542L (sv) Administreringssystem foer farmakologiska medel
ATE81287T1 (de) Am zielorgan wirkendes enterales abgabesystem.
KR880008803A (ko) 핵을 갖는 구형 과립 및 그의 제조방법
ATE217188T1 (de) Granulierte pharmazeutische zusammensetzung
AR022930A2 (es) MICROCAPSULAS, DE TIPO RESERVORIO, QUE CONTIENEN POR LO MENOS UN PRINCIPIO ACTIVO MEDICAMENTOSO Y/O NUTRITIVO (PA) CON EXCLUSION DEL ACIDO ACETILSALICILICO (ASA), DESTINADAS A LA ADMINISTRACION POR VIA ORAL, SU UTILIZACIoN Y FORMA FARMACEUTICA QUE COMPRENDE A DICHAS MICROCAPSULAS.
FI904207A0 (fi) Fettsyra-laekemedelkonjugat foer tillfoering av laekemedel genom blodhjaernbarriaeren.
NO975218D0 (no) Behandling av inflammatorisk tarmsykdom ved bruk av orale doseringsformer av omega-3-polyumettede syrer
ES2089844T3 (es) Sistema de administracion de medicamentos a base de dicetopiperazina.
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
EP0217778A3 (en) Galenical forms for the sustained release of verapamil, their preparation and medicaments containing them
SE8602722D0 (sv) Hallbara administreringsformer
ES2057537T3 (es) Sistema de dosificacion con emision continuada.
FI890782A (fi) Frigoerningssystem foer farmakologiska aemnen.
ATE104146T1 (de) Zubereitung mit verzoegerter freigabe eines hydrochlorids eines basischen arzneistoffs.
DK0896547T3 (da) Diagnostisk præparat
Madden et al. Some unusual aspects of microsphere migration at the microcirculatory level
JPS57106611A (en) Coating remedy
DE3688355D1 (de) Fester koerper mit ueberzogenem kern.
Fedan Facilitation of active defensive and clocking of passive defensive reactions in cats after transection of half of the mensencephalic tegmentum.
ES2008964A6 (es) Metodo para microencapsular un agente farmacologicamente activo.
PT86571B (pt) Metodo para a microencapsulacao de agentes farmacologicos e processo para a preparacao de composicoes farmaceuticas que contem esses agentes
TH33149A (th) สูตรผสมละอองลอยที่เป็นยา

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8900542-5

Format of ref document f/p: F